Project Grant HT9425261E407
Award Date 8/1/26
Completion Date 7/31/30
Dollars Obligated $2.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
- Federal Grant Award Summary The University of California, Los Angeles received a $1.7M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "The 3D Multiomic Determinants of Prostate Cancer Lethality." Awarded on June 1, 2026, with a completion date of May 31, 2029, this three-year initiative will investigate the molecular and genetic factors that drive prostate cancer progression and...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded University of California, Los Angeles a $2.08 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) beginning September 1, 2026, and concluding August 31, 2030. The award supports research to define an error-free DNA repair signature as a predictive marker for lethal prostate cancer. This research initiative aligns with the DHA's broader portfolio of biomedical research addressing...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded University of California, Los Angeles a $799,999 Project Grant on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support the project "From H&E to HRD: Linking Morphometry, Clinical, and Molecular Data for Drug Response Prediction." The award, with an ultimate completion date of April 30, 2030, funds biomedical research aimed at integrating histopathological imaging...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $235,476 project grant to the University of California, Los Angeles (UCLA) Office of Research Administration on November 1, 2025, to develop new cell-mediated immunotherapeutic strategies for neuroendocrine prostate cancer. The two-year award, which concludes October 31, 2027, is funded under the Military Medical Research and Development program (CFDA 12.420) and will be conducted at UCLA's Los Angeles, California facility....
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded UCLA a $1.7M Project Grant effective July 1, 2026, through June 30, 2029, under the Military Medical Research and Development program (CFDA 12.420) to conduct functional evaluation and optimization of chimeric antigen receptor T (CAR-T) cells targeting prostate cancer. The research will employ cell-cell interaction profiling using engineered nanovials as the primary analytical technology platform. This work addresses the DHA's...
- This federal Project Grant award, valued at $2,520,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The primary awardee, the University of California, Los Angeles (UCLA), will leverage its extensive facilities, diverse faculty expertise, and robust administrative capabilities...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded the University of California, Los Angeles (UCLA) a $590,625 Project Grant on September 1, 2025, under the Military Medical Research and Development program (CFDA 12.420) to conduct a pilot study investigating dual immunotherapy targeting PD-1 and CD73 in combination with chemotherapy for patients with pancreatic adenocarcinoma. The three-year award, extending through August 31, 2028, supports basic and applied biomedical...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded a $350,000 Project Grant to the University of California, Los Angeles (UCLA) on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420). The award supports the development of a polylactic acid (PLA)-based, immunohistochemistry (IHC)-compatible functional assay for detecting homologous recombination deficiency in ovarian cancer. The two-year project, scheduled for completion by...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $700,000 Project Grant to the University of California, Los Angeles (UCLA) beginning June 1, 2026, through May 31, 2030, under the Military Medical Research and Development program (CFDA 12.420). The project, titled "Early Detection of Ovarian Cancer with cfDNA Methylome Sequencing and Protein Biomarkers," focuses on developing innovative diagnostic approaches for ovarian cancer screening. The research will utilize...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded a $7.99 million Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420) to conduct a Phase 1 single-blind, placebo-controlled, dose escalation clinical safety study of AD-NP1, a humanized monoclonal antibody targeting human enpp1 (ectonucleotide pyrophosphatase/phosphodiesterase 1). The award, effective August 1, 2026, through July 31,...